Pfizer guides FY2024 rev $58.5-61.5B, adj EPS $2.05-2.25; Seagen closing Dec 14

PFIZER INC

FY2024 revenue guidance $58.5-$61.5B; includes ~$8B from Comirnaty/Paxlovid and ~$3.1B from Seagen.
FY2024 adjusted diluted EPS guidance $2.05-$2.25; includes ~$0.40 dilution from Seagen.
Cost realignment program now expected to deliver at least $4.0B annual net savings by end 2024.
Excluding COVID products and Seagen, operational revenue growth 3%-5% YoY.
Seagen acquisition has received all regulatory approvals; closing expected Dec 14, 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.